12-Nov-2026 13:13:00
CAPLIN POINT LABORATORIES Q2 FY27: H1 REVENUE CROSSES ₹1,300 CR, EBITDA ABOVE ₹500 CR; $10.3 MN LATAM TENDERS, 60+ INTERNATIONAL PRODUCT LAUNCHES PLANNED & US BUSINESS TARGETS DOUBLING FY26 REVENUE AND PROFIT
• H1 FY27 Performance: Revenue crossed ₹1,300 Cr and EBITDA exceeded ₹500 Cr, both growing approximately 20% YoY. • Central America Orders: Won tenders worth $5.3 Mn, executable over the next three quarters, with around 70% from oncology products. • Chile Business: Secured $5 Mn tenders for supply over 18 months; six products accepted by three major pharmacy chains. • Mexico Expansion: Received four new product approvals during Q2, with 13 applications under review and 110+ product filings planned over 18 months. • Oncology Pipeline: Kakkatur facility completed exhibit batches for four injectable and OSD products; plans submissions for 16 products over the next 12 months. • Oncology Acquisitions: Evaluating potential acquisition of 12+ oncology ANDAs. • API Expansion: Vizag API facility received commercial licence; oncology API facility in Tamil Nadu targeted for completion by CY27-end. • Pondicherry Expansion: OSD and dermatology capacity expansion progressing, targeting over 2x existing capacity. • International Launches: Caplin Steriles plans 60+ product launches across non-US markets over the next 18 months, supporting FY27–FY28 growth. • US Product Pipeline: Launched 40 products in the US, with another 10 launches planned for FY28. • US Business Growth: Caplin Steriles USA expects to double FY26 revenue and profit; average daily sales increased from $32,936 in FY26 to $61,330 currently. • US Customer Expansion: Customer base increased 20% to over 5,600, supported by additional wholesale distribution contracts. • Injectables Expansion: COL-II facility targeted for completion by August 2027, housing five injectable, ophthalmic and BFS lines, with provision for three additional lines. • Clinical Research: Amaris Clinical expanding capacity to 120 beds by FY27-end. • Cash Reserves: Strong cash position of ₹1,534 Cr supports investments in oncology, APIs, manufacturing and digitalisation. • Management Outlook: Positive on Latin American growth, US product launches, oncology expansion and increasing manufacturing capacity, supported by a strong balance sheet.
CAPLIN POINT LAB LTD.